Key Takeaway: The article discusses Skye's CBeyond Trial, which evaluates the efficacy of nimacimab in promoting weight loss compared to a placebo. The trial also investigates the effects of combining nimacimab with semaglutide versus semaglutide alone. This research aims to understand the mechanistic differences of nimacimab in treating obesity.
Price reaction · baseline $2.14 (2025-06-18 close) · hit pre-market · 6 other SKYE headline(s) in the window, move may be shared
day 0 close · peak
+0.9%
Market Sentiment Analysis
POSITIVE FACTORS
Nimacimab shows promise in weight loss treatment.
The trial compares nimacimab with a placebo, providing clear insights.
Combination therapy with semaglutide may enhance efficacy.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity
Full Press Release Details
Obesity is a complex disease that affects a substantial portion of the world’s population. CB1 receptors are related to every key organ that is related to metabolism, underlying the key effects of blocking these receptors in the clinic without ever crossing the blood brain barrier.
Skye’s CBeyond Trial proof of mechanism trial that compares weight loss in patients treated with nimacimab vs placebo. A second arm in the study compares the effect of nimacimab combined with semaglutide vs semaglutide alone given with placebo.
Frequently Asked Questions
What is the CBeyond Trial?
The CBeyond Trial is a proof of mechanism study evaluating nimacimab's effect on weight loss.
How does nimacimab work?
Nimacimab blocks CB1 receptors, which are linked to metabolism and obesity.
What does the trial compare?
It compares weight loss in patients treated with nimacimab versus a placebo.
Is there a combination therapy in the trial?
Yes, the trial includes a comparison of nimacimab with semaglutide versus semaglutide alone.